Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

United Therapeutics Corporation Reports First Quarter 2023 Financial Results

Business Wire May 3, 2023

United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023

Business Wire April 26, 2023

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings

Business Wire April 18, 2023

United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference

Business Wire March 6, 2023

United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference

Business Wire February 28, 2023

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 22, 2023

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023

Business Wire February 15, 2023

United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2023

United Therapeutics Named by Newsweek as One of America's Most Responsible Companies 2023

Business Wire December 8, 2022

United Therapeutics Corporation Reports Third Quarter 2022 Financial Results

Business Wire November 2, 2022

United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference

Business Wire November 1, 2022

United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy

Business Wire October 31, 2022

United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022

Business Wire October 26, 2022

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting

Business Wire October 14, 2022

United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis

Business Wire October 11, 2022

United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report

Business Wire September 12, 2022

3D Systems Announces Formation of New Biotech Company, Systemic Bio(TM), to Accelerate Drug Discovery and Development

GlobeNewswire September 8, 2022

United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation

Business Wire August 31, 2022

United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022

Business Wire August 24, 2022

United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

Business Wire August 3, 2022